No-response at mpMRI after neoadjuvant pembrolizumab is a proxy of adverse pathological and oncological outcomes in patients treated with radical cystectomy: interim results from the PURE01 study

No-response at mpMRI after neoadjuvant pembrolizumab is a proxy of adverse pathological and oncological outcomes in patients treated with radical cystectomy: interim results from the PURE01 study

Show other versions (1)
Bibliographic Details
Main Authors: G. Basile, M. Bandini, E. Zaffuto, S. Scuderi, F. Pederzoli, L. Marandino, D. Raggi, F. Barletta, G. Gandaglia, N. Fossati, G. Burgio, M. Moschini, S. Zamboni, L. Afferi, S. Comana, A. Briganti, F. Montorsi, R. Colombo, A. Necchi, A. Gallina
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:European Urology Open Science
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168320356172

Internet

http://www.sciencedirect.com/science/article/pii/S2666168320356172

Similar Items